Arjuna Therapeutics Overview

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Crowdfunding

  • Latest Deal Amount
  • $1.47M

  • Investors
  • 5

Arjuna Therapeutics General Information

Description

Developer of a novel class of orally available small molecules intended to address untreatable cancers. The company's nanomaterials aim to redefine the treatment landscape for solid tumors on both sides of the blood-brain barrier by targeting all cancers that generate high levels of Reactive Oxygen Species, enabling healthcare providers to treat cancer patients with novel drugs.

Contact Information

Formerly Known As
Nanogap Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • C-Da Xesta 78-a2
  • Ligonoindustrial Novo Milla (Ames)
  • 15895 A Coruna
  • Spain
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • C-Da Xesta 78-a2
  • Ligonoindustrial Novo Milla (Ames)
  • 15895 A Coruna
  • Spain

Arjuna Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arjuna Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Equity Crowdfunding 17-Oct-2022 $1.47M Completed Pre-Clinical Trials
7. Later Stage VC 14-Feb-2022 Completed Pre-Clinical Trials
6. Later Stage VC 20-Dec-2019 Completed Pre-Clinical Trials
5. Later Stage VC 11-Jan-2019 Completed Pre-Clinical Trials
4. Grant 20-Jan-2016 Completed Pre-Clinical Trials
3. Later Stage VC 23-Sep-2014 Completed Pre-Clinical Trials
2. Later Stage VC 16-Mar-2012 Completed Pre-Clinical Trials
1. Grant 01-Jan-2011 Completed Startup
To view Arjuna Therapeutics’s complete valuation and funding history, request access »

Arjuna Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
To view Arjuna Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Arjuna Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arjuna Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Repsol Corporate Venturing Corporate Venture Capital Minority
Horizon 2020 Government
Caixa Capital Risc Venture Capital Minority
Unirisco Venture Capital Minority
European Commission Government
To view Arjuna Therapeutics’s complete investors history, request access »

Arjuna Therapeutics FAQs

  • Where is Arjuna Therapeutics headquartered?

    Arjuna Therapeutics is headquartered in A Coruna, Spain.

  • What is the size of Arjuna Therapeutics?

    Arjuna Therapeutics has 10 total employees.

  • What industry is Arjuna Therapeutics in?

    Arjuna Therapeutics’s primary industry is Drug Discovery.

  • Is Arjuna Therapeutics a private or public company?

    Arjuna Therapeutics is a Private company.

  • What is the current valuation of Arjuna Therapeutics?

    The current valuation of Arjuna Therapeutics is .

  • What is Arjuna Therapeutics’s current revenue?

    The current revenue for Arjuna Therapeutics is .

  • How much funding has Arjuna Therapeutics raised over time?

    Arjuna Therapeutics has raised $8.61M.

  • Who are Arjuna Therapeutics’s investors?

    Repsol Corporate Venturing, Horizon 2020, Caixa Capital Risc, Unirisco, and European Commission have invested in Arjuna Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »